Larrañaga-Vera, Ane
Marco-Bonilla, Miguel
Largo, Raquel
Herrero-Beaumont, Gabriel
Mediero, Aránzazu
Cronstein, Bruce
Funding for this research was provided by:
ISCIII (PI16/00991, PI19/00991)
NIH (R01 AR068593)
NYU-HHC Clinical and Translational Science Institute (UL1 TR000038)
Article History
Received: 12 April 2021
Accepted: 9 July 2021
First Online: 15 August 2021
Declarations
:
: A.M. has filed a patent on the use of adenosine A2AR agonists to prevent prosthesis loosening (pending) and a separate patent on the use of A2AR agonists and agents that increase adenosine levels to promote bone formation/regeneration. R.L. and G.H.-B. have filed a patent on the use of 6-shogaol in osteoarthritis. A.L.-V. and M.M.-B. have no conflicts of interest. B.C. has consulted for Eli Lilly & Co., Horizon Pharmaceuticals, and AstraZeneca. B.C. is a founder and Director of the Scientific Advisory Board of Regenosine, Inc. and has equity in Regenosine, Inc.
: Not applicable.
: Not applicable.